E-mail this story
State biotech firms hope Congress will act
A proposal to speed the approval of new prescription drugs has patient advocates and biotech firms — including many based in Maryland — hoping that Congress will deliver a rare dose of bipartisanship this year.
By John Fritze, The Baltimore Sun
May 5, 2012